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Dialysis dose and the effect of gender and body size on outcome
in the HEMO Study.
Background. Gender and body size have been associated
with survival in hemodialysis populations. In recent observa-
tional studies, overall mortality was similar in men and women
and higher in small patients. The effect of dialysis dose in each
of these subgroups has not been tested in a clinical trial.
Methods. The HEMO Study was a controlled trial of dialysis
dose and membrane flux in 1846 hemodialysis patients followed
up for 6.6 years in 15 centers throughout the United States. We
examined the effect of dialysis dose on mortality and on selected
secondary outcomes in subgroups of patients.
Results. Adjusting for age only, overall mortality was lower in
patients with higher body weight (P < 0.001), higher body mass
index (P < 0.001), and higher body water content determined
by the Watson formula (Vw) (P < 0.001), but was not associated
with gender (P = 0.27). The RR of mortality comparing the high
dose with the standard dose group was related to gender (P =
0.014). Women randomized to the high dose had a lower mor-
tality rate than women randomized to the standard dose (RR =
0.81, P = 0.02), while men randomized to the high dose had a
nonsignificant trend for a higher mortality rate than men ran-
domized to the standard dose (RR = 1.16, P = 0.16). Analysis
of both genders combined showed no overall dose effect (R =
0.96, P = 0.52), as reported previously. Vw was greater than
35 L in 84% of men compared with 17% of women. However,
the RR of mortality for the high versus standard dose remained
lower in women than in men after adjustment for the interac-
tion of dose with Vw or with other size parameters, including
weight and body mass index. Conversely, the dose effect was
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not significantly related to size parameters after controlling for
the relationship of the dose comparison with gender.
Conclusion. The data suggest that mortality and morbidity
might be reduced by increasing the dialysis dose above the cur-
rent standard in women but not in men. This effect was not
explained by differences between men and women in age, race,
or in several indices of body size. Because multiple comparisons
were considered in this analysis, the role of gender on the effect
of dialysis dose is suggestive and invites further study.
The Hemodialysis (HEMO) Study was a prospective,
randomized, multicenter clinical trial designed to de-
termine if increasing the dose of hemodialysis or using
high-flux membranes can affect mortality and morbid-
ity. Patients with end-stage renal disease (ESRD) were
randomly assigned to two different levels of dialysis dose,
expressed as Kt/V, and to treatment with either a high-flux
or a low-flux membrane. In intent-to-treat analyses of all
patients, neither the high- nor the low-dose intervention
significantly improved mortality or any of four prespeci-
fied main secondary outcomes, but a possible interaction
with gender was identified [1].
Several observational studies have examined the re-
lationship between dialysis dose and survival stratified
by gender, race, or a measure of body size [2–5]. Owen
et al [2] specifically suggested that the effects of dialy-
sis dose can vary depending on race and gender. Several
other observational studies have also reported that larger
body size is associated with lower mortality, irrespective
of dialysis dose [5–7]. Over the past decade, data from the
United States Renal Data System (USRDS) have shown
a lesser trend downward in the absolute mortality rate of
women compared with men, resulting in reversal of the
relative mortality rate, which is now higher in women. [8].
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A J-shaped pattern to the overall dose-mortality curve,
reported in several studies, has been attributed to effects
of nutrition and body size, and to gender as well [2, 4,
8, 9]. Men are larger on average than women and may
require more time on dialysis to achieve the same Kt/V.
Therefore, gender and other linked variables can affect
the dose-survival analysis. As a result, it has been difficult
to separate the independent effects of gender, treatment
time, and body size.
Using HEMO Study data, we examined the effects of
race, gender, body size, and other variables as predictors
of outcome, and we examined subgroups of patients in
whom the dose intervention might have affected survival.
METHODS
Details of the study design, primary outcomes, and the
characteristics of 1846 randomized patients have been
published and are briefly summarized [1, 10]. Patients 18
to 80 years of age who were on dialysis at least 3 months,
and had less than 1.5 mL/min/35 L residual urea clearance
were enrolled between March 1995 and October 2000,
and were followed up to 6.6 years. Half were dialyzed
with a target equilibrated Kt/V (eKt/V) of 1.45, and half
were treated with a target eKt/V of 1.05. Randomization
was stratified by clinical center, age, and diabetic status.
To qualify for randomization, each patient had to achieve
an eKt/V greater than 1.30 within 4.5 hours of treatment
during the baseline period. This criterion resulted in ex-
clusion of very large patients (3% of randomized patients
>100 kg). The dose was adjusted by changing either clear-
ance (blood flow, dialysate flow, or dialyzer model) or
treatment time, while encouraging the prescribing physi-
cian to shorten the dialysis as much as possible, but not
below 2.5 hours, while maintaining fluid removal. Urea
kinetics were modeled each month and tracked by an
adherence committee. Serum tests for albumin (by neph-
elometry) and other commonly measured solutes were
obtained at monthly intervals of predialysis. A patient’s
racial/ethnic classification was based on self reports.
The study protocol was approved by the institutional
review board at each of the 15 clinical centers associ-
ated with a total of 72 participating dialysis clinics. Writ-
ten consent was obtained from each patient at entry into
baseline and before randomization.
Outcome measures
The primary outcome of the HEMO Study was all-
cause mortality. The four main secondary outcomes were
the rate of nonaccess hospitalizations, and three compos-
ite outcomes: first cardiac hospitalization or death from
any cause, first infection-related hospitalization or death
from any cause, and first 15% decline in serum albumin
or death from any cause. Additional secondary outcomes
considered in this report included death from cardiac
causes, death from infection, the composite of first cardiac
hospitalization or death from cardiac causes, the compos-
ite of first infection-related hospitalization or death from
infection, the first access-related hospitalization, and the
first access-related event. The first access event was de-
fined as either the first recorded access-related hospital-
ization or the first access procedure of any type recorded
monthly in the study database.
Size variables and other baseline measurements
Total body water volume (Vw) was determined by the
Watson anthropometric formula [11]. Body mass index
(BMI) was defined as body weight in kg divided by the
square of height in cm. Urea distribution volume (V) was
assessed monthly using single-pool urea kinetic analy-
sis adjusting for the double-pool error [12–14]. Baseline
postdialysis weight used to compute anthropometric vol-
ume, and the baseline modeled urea volume was aver-
aged over two kinetic modeling sessions conducted on
the patient’s usual dialysis prescriptions.
Interactions
Seven baseline variables: age, gender, race, years on
dialysis, diabetes, index of coexisting disease (ICED), and
serum albumin, were prespecified by the HEMO investi-
gators at the beginning of the trial as covariates in the pri-
mary statistical analyses and for subgroup analyses. The
ICED score was defined as described previously [15], but
excluding diabetes because diabetic status is a separate
factor in analysis.
In this report we use the term “interaction” to describe
differences in the effect of the dose intervention between
different subgroups of patients. We applied statistical
tests for interactions to see if the dose effect differed be-
tween subgroups defined by the above seven prespecified
covariates and the size variables listed previously. In par-
ticular, the interaction between the dose intervention and
gender refers to the difference between the effect of the
dose intervention in females compared with males, and is
quantitatively expressed as the ratio of the relative risk
for the high versus standard dose group in women to the
relative risk for the high versus standard dose group in
men. Because the relative risk is itself a ratio, the prin-
cipal expression of interaction shown in Tables 5 and 6
(columns headed “Ratio of RR”) is a ratio of a ratio.
Statistical methods
The primary analysis of the effects of the dose and flux
interventions on all-cause mortality was conducted with
Cox regression stratified by clinical center and control-
ling for the seven prespecified baseline covariates, and for
the interaction of baseline albumin with follow-up time.
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Follow-up was censored after kidney transplants. Addi-
tional details regarding the primary analysis have been
provided elsewhere [1, 2].
The interactions of the dose intervention with each of
the seven prespecified baseline factors on mortality were
individually tested by adding an interaction term between
the dose intervention and the designated baseline factor
to the basic Cox regression model described above. In
the initial prespecified analyses, subgroups for continuous
factors (age, albumin, and years on dialysis) were defined
by their mean values.
After identification of a potential interaction between
the dose intervention and gender on mortality, we per-
formed similar analyses to test for interactions between
dose and gender on the secondary outcome variables.
These analyses were performed with overdispersed Pois-
son regression for the nonaccess hospitalization rate, and
Cox regression analysis for each of the other compos-
ite outcomes. In the analyses of the secondary outcomes,
follow-up was censored at transfer to nonparticipating
dialysis units and at renal transplant. Follow-up time was
also censored at death for the analyses of the nonaccess
hospitalization rate, first access hospitalization, and first
access event.
Additional Cox regression analyses were performed to
individually test for interactions of the dose intervention
with specific size parameters, while controlling for the
seven prespecified covariates and the interaction of base-
line albumin with follow-up time as in previous analyses.
The size parameters were treated as continuous variables
in these analyses, allowing tests of linear interactions. A
further analysis was conducted by stratifying Vw into four
quartiles to investigate the possibility of a nonlinear in-
teraction. These models were next augmented to include
two separate interaction terms, one of dose group with
the size parameter being evaluated, and the other of dose
group with gender. These analyses evaluated the extent
to which trends for interactions between dose and the
respective size parameters persisted after taking into ac-
count the interaction between gender and the size param-
eters, and conversely, the extent to which the interaction
of dose group with gender persisted after taking into ac-
count any interaction between dose group and the size
parameters. As in the primary analysis, all of the Cox re-
gression analyses of mortality were stratified by clinical
center and censored transplants.
All analyses in this report are based on comparisons of
the randomized dose groups rather than the achieved lev-
els of eKt/V. All reported P values are two-sided without
adjustment for multiple comparisons.
RESULTS
Among the seven prespecified variables, gender was
the only factor that had a significant interaction with the
Table 1. Effects of seven prespecified baseline factors on the
response to high Kt/V
Relative
Factor Subgroup riska 95% CI P valueb
Agec ≤58 years 0.95 (0.74–1.22)
>58 years 0.97 (0.82–1.13) 0.92
Gender Men 1.16 (0.94–1.43) 0.014
Women 0.81 (0.68–0.97)
Race Non-black. 1.13 (0.91–1.39) 0.060
Black 0.87 (0.73–1.03)
Diabetes Nondiabetic 0.90 (0.74–1.09) 0.35
Diabetic 1.02 (0.85–1.23)
Years of dialysisc ≤3.7 years 1.03 (0.88–1.22) 0.12
>3.7 years 0.83 (0.66–1.04)
ICEDc ≥2 0.92 (0.70–1.22) 0.96≤3 0.93 (0.76–1.15)
Albuminc ≤3.6 g/dL 0.89 (0.75–1.06) 0.16
>3.6 g/dL 1.08 (0.88–1.32)
ICED, Index of Coexisting Diseases.
aRelative risk of mortality from any cause in high vs. standard Kt/V group.
bP values for interactions were based on comparisons without adjustment for
multiple tests. Bonferroni limit for 7 variables = 0.0071.
cInteraction tests for continuous variables were based on dichotomization at
their mean values.
dose intervention on mortality (P = 0.014) (Table 1).
Women appeared to respond to the high dose with a
19% reduction in mortality, whereas the mortality in men
trended upward by 16% at higher doses. Kaplan-Meier
survival curves comparing the dose interventions in men
and women separately showed a similar lower mortal-
ity in women on the higher dose and the opposite effect
in men (Fig. 1). The remainder of this report examines
the relationship between gender and the effect of dose in
greater detail, and in particular investigates if the inter-
action between dose and gender can be accounted for by
body size or other factors that are associated with gender.
Genders differences at baseline
Although randomization was not stratified by gen-
der, female percentages were well-balanced, at 56%
of patients in each of the treatment groups [1]. The
women were slightly but significantly older than the men
(Table 2). Blacks have a known survival advantage, and
diabetes mellitus, a known survival disadvantage, were
both over-represented in the women [2, 8]. The indices
of body size listed in Table 2 were lower in women than
in men. Histograms of body water in men compared with
women, shown in Figure 2, revealed limited overlap. The
type of vascular access, a factor previously shown to be
associated with survival [16], appeared to disadvantage
women who had more grafts and catheters than men at
baseline (Table 2).
Each of these differences between the genders at base-
line was investigated as a possible explanation for the
relationship between gender and the effect of dose on
outcome. None of the prespecified covariates, or the three
baseline treatment parameters listed in Table 2 other than
gender, had a statistically significant interaction with the
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Fig. 1. Kaplan Meier curves showing time to death in women by ran-
domized treatment group (484 total deaths) (A). The high-dose group
(dashed line) had a relative mortality risk of 0.81 compared with the
standard dose group (solid line); 95% CI, 0.67–0.97, P = 0.02. Numbers
of patients remaining in follow-up are provided for the high dose (top
line) and standard dose (bottom line). Similar analysis showing time to
death in men (387 total deaths) (B). In contrast to women, the high-dose
group (dashed line) had a relative mortality risk of 1.16 compared with
the standard dose group (solid line), 95% CI, 0.94–1.43, P = 0.16. Num-
bers of patients remaining in follow-up are provided for the standard
dose (top line) and high dose (bottom line).
dose (P > 0.05 for all interaction tests), and the dose ×
gender interaction persisted after controlling for the in-
teractions of dose with each of these other factors.
Causes of death in women
The higher dose in women was associated with fewer
deaths caused by ischemic heart disease (53 in the high
dose group vs. 65 in the standard dose group), cerebrovas-
cular disease (15 vs. 25), congestive heart failure (5 vs. 10),
and vascular access complications (12 vs. 21). Smaller dif-
ferences were observed in women for deaths from other
causes, including peripheral vascular disease (19 vs. 16)
and malignancy (13 vs. 14).
Overall association of gender with mortality
Because of their smaller size, women required less time
and lower urea clearances to achieve their targeted goals
(Table 3). The absolute separation between standard and
high-dose dialysis during follow-up was similar (0.37 and
0.38 eKt/V units in men and women, respectively), de-
spite the higher average eKt/V and urea reduction ratio
(URR) in women and the lower predialysis blood urea
nitrogen (BUN). Adjusting only for treatment group, the
relative risk of mortality (RR) in women compared with
men in the two dose groups combined was 1.02 (95% CI,
0.89–1.16, P = 0.83). After controlling for age and treat-
ment group, the RR decreased to 0.93 (95% CI 0.81–1.06,
P = 0.27), and after controlling for all six remaining pre-
specified covariates and stratifying by clinical center, RR
decreased to 0.85 (95% CI 0.74–0.98, P = 0.02). Thus,
there appeared to be a moderate overall survival advan-
tage of women compared with men with similar initial
baseline risk factors. This perhaps reflects the longer life
expectancy for women in the general population.
Overall association of body size and race with mortality
When averaged over both dose groups, a lower overall
mortality rate was associated with larger body size and
among blacks (Table 4; column 3). These relationships
persisted after controlling for gender (Table 4; column 5).
The data are consistent with previous reports of cross-
sectional data [5] that showed a lower risk of mortality in
larger patients and in blacks.
Interactions of dose with body size and their relationship
to gender
The third and fourth columns of Table 5 summarize
analyses of interactions between the dose intervention
and various baseline parameters related to body size and
race. A ratio of relative risks (RR) greater than 1 means
that larger values of the baseline parameter are associated
with a higher risk of death at the high dose compared
with the standard dose intervention, while an RR ratio
less than 1 means that larger values are associated with
a reduced risk at the high dose. None of the examined
indices of body size had significant interactions with dose
(P ≥ 0.19).
The final two columns of Table 5 show the interactions
between the dose intervention and the same body size pa-
rameters after controlling for the interaction of dose with
gender. The weak trends that were observed for higher
mortality in the high dose compared with the standard
dose group for higher height, Vw, and modeled volume
(interaction P values 0.19 to 0.26), dissipated after con-
trolling for the interaction of dose with gender. This is
illustrated in greater detail for Vw in Figure 3.
Table 6 provides the converse of the analysis displayed
in the final two columns of Table 5 by showing the strength
of the interaction of dose with gender after adjusting
for the interactions of dose with the respective size pa-
rameters. Several of the size parameters were strongly
associated with gender (see Table 2), potentially mak-
ing it difficult to distinguish between gender and body
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Table 2. Description of randomized patients at baseline by gender
All (N = 1846) Men (N = 808) Women (N = 1038) P valuea
Prespecified covariates
Age years 57.6 ± 14.0b 56.6 ± 14.5 58.4 ± 13.6 0.005
% Black race 62.6% 55.0% 68.6% <0.001
% Diabetic 44.6% 37.0% 50.5% <0.001
Years on dialysis 3.75 ± 4.36 4.02 ± 4.58 3.54 ± 4.16 0.021
ICED score 1.97 ± 0.83 1.91 ± 0.85 2.02 ± 0.82 0.003
Albumin g/dLc 3.62 ± 0.36 3.70 ± 0.37 3.56 ± 0.34 <0.001
Baseline treatment parameters
Equilibrated Kt/V eKt/V 1.43 ± 0.21 1.37 ± 0.19 1.48 ± 0.22 <0.001
Single-pool Kt/V spKt/V 1.60 ± 0.23 1.52 ± 0.20 1.66 ± 0.24 <0.001
URR 72.7 ± 4.9 71.0 ± 4.6 74.0 ± 4.7 <0.001
% with residual urea clearance >0 32.9% 35.1% 31.1% 0.07
Size parameters:
Weight kgd 69.2 ± 14.7 72.1 ± 13.6 66.8 ± 15.1 <0.001
Height cm 165 ± 9.4 171 ± 7.7 159 ± 7.1 <0.001
BMI kg/cm2 25.5 ± 5.3 24.5 ± 4.3 26.2 ± 5.8 <0.001
BSA m2 1.75 ± 0.20 1.83 ± 0.18 1.68 ± 0.18 <0.001
Vw L 34.9 ± 6.1 39.6 ± 5.0 31.3 ± 4.0 <0.001
Creatinine mg/dLc 10.3 ± 2.9 11.2 ± 3.1 9.5 ± 2.5 <0.001
Vascular accesse
Native fistula 34.5% 48.9% 23.2% <0.001
Synthetic graft 59.4% 47.8% 68.4% <0.001
Catheter 5.6% 3.5% 7.3% <0.001
Abbreviations are: ICED, Index of Coexisting Diseases; URR, urea reduction ratio; BMI, body mass index; BSA, body surface area; Vw, total body water volume.
aComparison between men and women.
bMean values ± SD.
cPredialysis.
dPostdialysis.
e0.5% of accesses classified as “Other.”
size when interpreting interactions with the dose inter-
vention. Nonetheless, when an adjustment was made for
each of the size parameters, the gender interaction with
dose remained, as shown in Table 6. These results indicate
that within the HEMO Study the evidence suggesting a
different dose effect between men and women was not
explained by differences in body size between the two
genders.
Interactions among race, gender, and dialysis dose
An interaction of borderline significance between
racial/ethnic group and dose on mortality was detected
(P = 0.060) (Table 1). Although weak, the interaction
raised the possibility that the gender effect might be ex-
plained in part by race. However, the gender interaction
with dose persisted after controlling for the interaction
of race with dose (Table 6, bottom row), while the race
interaction with dose weakened after controlling for the
interaction of gender with dose (Table 5, bottom row).
The evidence for a different effect of dose between
men and women was stronger in non-blacks in whom the
RRs for the high- versus the standard-dose groups were
0.80 (95% CI 0.58–1.10) for women, compared with1.47
(95% CI 1.11–1.96) for men. Among blacks, the RRs for
the high- versus the standard-dose groups were 0.84 (95%
CI 0.68–1.04) for women, compared with 0.91 (95% CI
0.69–1.21) for men. Thus, it appears that the gender ef-
fect was driven by the response to the higher dose in non-
blacks. Although the magnitude of the effect of race on
the dose by gender interaction appears substantial, the
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Fig. 2. Distribution of body water volumes (Vw) by gender. Vw, pre-
dicted by the Watson anthropometric formula [11], were in general
much lower in female than in male patients assigned to randomized
groups in the HEMO Study.
difference in the dose by gender interactions between
blacks and non-blacks did not reach statistical signifi-
cance (P = 0.064). This reflects the very low power of
this study (as is generally the case in clinical trials) to
detect a three-way interaction.
Treatment time and other variables
The mean treatment time was shorter in women than
in men, and even shorter in women randomized to the
standard dose (Table 3). The HEMO Study was inten-
tionally designed to allow time to vary within limits to
reflect the standard of hemodialysis care in the United
States. Centers were advised to select a prescription with
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Table 3. Treatment parameters during follow-up by gendera
All Women Men
Parameter Standard Dose High Dose Standard Dose High Dose Standard Dose High Dose
Dialysis time (T) minutes 190 ± 23 219 ± 23 182 ± 21 210 ± 20 200 ± 21 231 ± 22
Blood flow rate mL/min 311 ± 51 375 ± 32 295 ± 51 367 ± 36 330 ± 43 385 ± 23
Urea clearance (K) mL/min 218 ± 25 251 ± 18 210 ± 24 247 ± 18 228 ± 21 257 ± 16
Urea K × T L 41.4 ± 7.0 55.1 ± 7.6 38.2 ± 5.9 51.7 ± 6.3 45.5 ± 6.1 59.6 ± 6.8
spKt/V 1.32 ± 0.09 1.71 ± 0.11 1.34 ± 0.10 1.73 ± 0.11 1.30 ± 0.07 1.68 ± 0.10
eKt/V 1.16 ± 0.08 1.53 ± 0.09 1.17 ± 0.09 1.55 ± 0.10 1.14 ± 0.06 1.51 ± 0.09
URR % 66.3 ± 2.5 75.2 ± 2.5 66.9 ± 2.6 75.7 ± 2.5 65.6 ± 2.2 74.5 ± 2.3
Predialysis BUN mg/dL 62.1 ± 13.6 54.3 ± 11.8 61.6 ± 12.9 54.0 ± 11.7 62.8 ± 14.4 54.8 ± 11.8
Summarized are the mean ± SD of these average values for all patients.
aTreatment parameters were first averaged over time for each patient with >4 months of follow-up.
Table 4. Association between various size parameters and the risk of mortality (RR) with or without adjustment for gender
Effect on mortality
Mean ± SD Effect on 95% Confidence controlling for 95% Confidence
Size arameter or % mortality RR Interval gender RR Interval
Weight kg 69.2 ± 14.7 0.88b (0.82–0.94) 0.87b (0.81–0.94)
Height cm 164.6 ± 9.4 0.95 (0.89–1.02) 0.93 (0.93–1.01)
Vw L 34.9 ± 6.1 0.85b (0.79–0.91) 0.73b (0.66–0.81)
Modeled V L 31.1 ± 6.6 0.90a (0.84–0.96) 0.88b (0.81–0.95)
Body surface area m2 1.75 ± 0.20 0.88b (0.82–0.94) 0.86b (0.80–0.93)
Body mass index kg/m2 25.5 ± 5.3 0.90a (0.84–0.96) 0.89a (0.83–0.96)
Black race 62.6% 0.74b (0.64–0.84) 0.73b (0.64–0.84)
Except for race and gender, the relative risk (RR) of mortality is expressed for one SD increase in size parameter. In the third column, RR is controlled only for the
randomized treatment group. In the fifth column, the RR is controlled for gender in addition to treatment group. In the last (bottom) line, blacks are compared with
non-blacks. Race and each size parameter are evaluated independently, without adjustment for the other size parameters.
aP < 0.05; bP < 0.001.
the highest clearance, and therefore, the shortest treat-
ment time consistent with the patient’s assigned dose.
Because of this design, the study was not optimized to
evaluate the effect of treatment time, which was largely
determined by the randomized dose assignment, volume
of urea distribution, and the ability of the patient’s ac-
cess to sustain a high blood flow. Recognizing this major
limitation, a series of multivariable time-dependent Cox
regression analyses were performed to relate risk of mor-
tality to the mean follow-up treatment time with several
different strategies that adjusted for baseline and follow-
up factors. No adverse effects of shorter treatment times
were detected (data not shown).
Additional factors that had no apparent effect on the
relationship of mortality to dose included the patient’s
native kidney urea clearance (Table 2), baseline serum
phosphorus, baseline dialyzer flux, baseline eKt/V, and
randomized flux group (P > 0.30). No change in the
relative risk for the comparison of the high- versus the
standard-dose groups was detected between the first two
years after randomization and subsequent follow-up (P =
0.97).
Secondary outcomes and gender
Table 7 shows the relationship of gender to the effect
of dose on ten secondary outcomes, including the four
main secondary outcomes stipulated in the study proto-
col. Consistent with the analyses of mortality, the relative
risk of the high- versus standard-dose was generally lower
in women. However, the P value for the dose by gender
interaction was smaller than 0.05 only for the following
outcomes: first infection-related hospitalization or death
from any cause; cardiac death; first 15% decline in serum
albumin or death from any cause; and first access hos-
pitalization. For the latter two outcomes, differences in
the dose effect between genders were primarily caused
by an adverse effect of the high dose in men rather than
a beneficial effect in women.
DISCUSSION
Despite the overall lack of improvement in outcome
from either a higher dose or higher flux, women in the
HEMO Study appeared to have a 19% lower mortality
risk (P = 0.02) when randomized to the higher dose of
dialysis, whereas the mortality risk in the men actually
rose 16% above that in men randomized to the standard
dose of dialysis (P = 0.16) (Fig. 1). Gender was the only
factor from among seven prespecified variables to exhibit
such an effect (Table 1). Diabetics, older patients, patients
with higher comorbidities, and non-blacks fared no better
at the higher dose compared with the standard dose, de-
spite the strong association of these variables with death
(Table 4). Although the strong association of gender with
body size makes it difficult to distinguish between the ef-
fects of these factors, differences in size did not appear
in our analyses to account for gender effect (Table 6),
whereas adjustment for gender reduced nearly all of
the size parameter interactions to an insignificant level
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Table 5. Effect of size on the mortality response to dialysis dose, with
or without controlling for gender
Effect on
response
to dose,
controlling
for the
interaction
Effect on between
response dose
to dose and gender
Size Mean ± SD Ratio Ratio
parameter or % of RRs P value of RRs P value
Weight kg 69.2 ± 14.7 0.98 0.83 0.95 0.53
Height cm 164.6 ± 9.4 1.09 0.19 0.98 0.78
Vw L 34.9 ± 6.1 1.09 0.26 0.96 0.64
Modeled V L 31.1 ± 6.6 1.10 0.20 1.02 0.77
Body surface 1.75 ± 0.20 1.02 0.84 0.95 0.48
area m2
BMI kg/m2 25.5 ± 5.3 0.93 0.32 0.95 0.52
Black race 62.6% 0.77 0.063 0.81 0.15
Data shown in the third and fifth columns are the ratios of the relative risk
(RR) of mortality for the high vs. standard dose groups per one SD increase in
size parameter (except for race, where the ratio of the RR is expressed for blacks
vs. non-blacks). The third column summarizes analyses of interactions between
the dose intervention and various baseline parameters related to body size and
race. Ratios of RR greater than 1 indicate a greater relative risk of the high
compared to the standard dose at higher values of the size parameter than at
smaller values. Ratios of RRs are provided without (third column) and with (fifth
column) adjustment for the interaction of dose group with gender. All analyses
are adjusted for the other six prespecified baseline covariates. P values are not
adjusted for multiple analyses.
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Fig. 3. The relative risk of death in the high dose compared with the
standard dose group showed a weak relationship with baseline body
water volume (Vw) () that disappeared after adjustment for gender
(). The number of women with Vw less than 30 L was 97.7% compared
with 7.3% with Vw greater than 40 L.
(Table 5). The predominance of the gender effect in-
dependent of size suggests that other gender-specific
characteristics influenced the response to the high dose.
Analysis of secondary outcomes also suggested that the
higher dialysis dose was effective in reducing morbidity
in women but not in men (Table 7).
Table 6. Effect of gender on the mortality response to dialysis dose,
modulated by size
Effect of gender on
Size parameter used response to high dose
to control the effect controlling for size parameter
of gender Ratio of RR P value
None 0.71 0.014
Weight kg 0.73 0.023
Height cm 0.69 0.039
Vw L 0.70 0.047
Modeled V L 0.74 0.052
Body surface area m2 0.70 0.019
BMI kg/m2 0.75 0.037
Black race 0.74 0.032
Shown in the second column are the ratios of relative mortality risk (RR) in
the high vs. standard dose groups in women compared with men after adjustment
for the interaction of dose group with the specified size parameter. Ratios of
RR <1 indicate a greater trend towards a benefit of the high dose in women than
in men. All RRs were adjusted for the other six prespecified baseline covariates.
P values are not adjusted for multiple comparisons.
Interpreting subgroup results in the context of multiple
comparisons
For randomized clinical trials, the primary intent-to-
treat analysis conducted in all randomized patients is
given high priority, while results observed in subgroups
of the full study population are interpreted with con-
siderable caution. The data presented here, suggesting a
benefit of the high-dose intervention in women, must be
interpreted in this context. The P value for the hypoth-
esis that the dose effect differed between women and
men was 0.014, which is smaller than the 0.05 significance
level typically used for testing an a priori hypothesis, but
larger than the Bonferroni critical value of 0.0071, which
is required to test separate interactions between the dose
intervention and seven baseline factors. It is also impor-
tant to note that the statistical significance of the dose by
gender interaction depends in part on the trend for an ad-
verse effect of the high dose in men. The degree to which
this evidence supports a true dose by gender interaction
depends on its biological plausibility, and the consistency
of findings both within the HEMO Study database and in
other studies. These issues are examined below.
Possible explanations for an improved outcome in women
but not in men
An adverse effect of the high dose in men? In men
there was not only a nonsignificant trend for increased
mortality in the high-dose group compared with the stan-
dard dose group, but the high-dose intervention was as-
sociated with increased risk (with P < 0.05) for five of
the 10 secondary outcomes summarized in Table 7. It is
possible that both genders benefited equally from the im-
proved solute removal expected at the high dose, but a
separate adverse effect of the high dose in men reduced
male survival, canceling the beneficial effect. Of inter-
est, the reverse J-shaped curve of survival reported in
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Table 7. Secondary outcomes: dose-gender interactions
All patients Men Women
# Events per Interaction
100 patient years RR 95% CI P value RR 95% CI P value RR 95% CI P value P valuea
All-cause mortality (acM) 871 (16.6) 0.96 (0.84–1.10) 0.53 1.16 0.94–1.43 0.16 0.81 0.67–0.97 0.02 0.014
Main secondary outcomes
1st cardiac hospitalization 1079 (28.5) 0.99 (0.88–1.12) 0.91 1.03 0.86–1.24 0.73 0.95 0.81–1.11 0.49 0.48
or acM
1st infection-related 1104 (29.9) 0.97 (0.86–1.09) 0.60 1.16 0.97–1.39 0.09 0.83 0.71–0.98 0.025 0.006
hospitalization or acM
1st albumin event or acM 1011 (24.5) 1.03 (0.91–1.17) 0.66 1.23 1.02–1.49 0.028 0.88 0.75–1.04 0.14 0.009
All nonaccess hospitalizations 6087 (125) 0.95 (0.86–1.05) 0.35 0.98 0.84–1.16 0.84 0.94 0.83–1.06 0.30 0.63
Other secondary outcomes
Cardiac death 343 (6.6) 1.03 (0.83–1.27) 0.80 1.39 1.01–1.90 0.042 0.81 0.61–1.09 0.16 0.014
1st cardiac hospitalization 835 (22.0) 1.00 (0.87–1.15) 0.99 1.04 0.85–1.28 0.68 0.97 0.81–1.16 0.75 0.60
or cardiac death
Infection-related death 201 (3.8) 0.99 (0.75–1.31) 0.94 1.00 0.64–1.55 0.99 0.99 0.69–1.42 0.95 0.97
1st infection hospitalization 802 (21.7) 0.94 (0.82–1.09) 0.42 1.06 0.86–1.31 0.57 0.86 0.71–1.03 0.10 0.13
or infection-related death
1st access hospitalization 685 (19.3) 1.05 (0.90–1.22) 0.56 1.37 1.07–1.75 0.013 0.90 0.74–1.09 0.27 0.008
1st access event 1085 (40.5) 1.07 (0.95–1.20) 0.29 1.25 1.03–1.51 0.022 0.98 0.84–1.14 0.77 0.050
aTests interaction between dose (high vs. standard Kt/V) and gender (men vs. women).
observational data that shows higher mortality at high
URR or Kt/V was seen only in men [2]. Although a com-
mon explanation for the lower survival at high doses seen
in these observational studies is that a disproportionate
number of clinically deteriorating small malnourished pa-
tients receives large doses of dialysis, this theory would
not explain the exclusive effect in men. Another possible
explanation is that hemodialysis has adverse effects that
are accentuated at the higher clearances required to ad-
equately dialyze men in comparison with women [4]. In
the HEMO Study, this adverse effect was seen primarily
in non-blacks, and as part of a post hoc analysis, so its
significance is not certain.
Higher generation rate of uremic toxins in women?
High toxin generation rates (G) counteract the beneficial
effect of dialyzer clearance. In a steady state of genera-
tion and removal, C = G/K, where C is the concentration
and K is the clearance. Toxin generation is assumed to
vary with body size, so it is logical to normalize the ef-
fect of dialyzer clearance to an index of size such as V,
a large component of which is muscle mass. However,
the generation rate of uremic toxins may be more closely
linked to another index of body size that does not in-
clude muscle mass [abstract; J Am Soc Nephrol 12:452A,
2001]. If this were true, then dosing dialysis based on Kt/V
might result in a higher toxin concentration in women,
which would shift their dose × concentration curve to
the right, accounting for the higher sensitivity to dose.
It is of interest that in hemodialysis patients mortality is
affected by anthropometric V independent of the dial-
ysis dose expressed as Kt/V (i.e., larger patients have a
lower mortality than smaller patients treated with the
same Kt/V) [2, 4, 5]. The reason for the independent
effect of V is not clear but has been presumed, largely
without evidence, to be nutritional. In the HEMO Study,
women constituted the majority of patients with low Vw
(97.7% of patients with Vw <30 L), and were under–
represented in patients with high Vw (7.6% of patients
with Vw >40 L) (see Fig. 2). So far, efforts to derive
a function of body size that would eliminate the gen-
der effect in the HEMO Study have been unsuccessful
(Table 5).
Increased sensitivity to uremic toxicity in women?
Failure to find a denominator that eliminates or normal-
izes the effect of gender suggests that women may be in-
trinsically more sensitive to equivalent toxin levels. This
theoretical sensitivity to uremic toxicity contrasts with
other life-threatening occurrences such as hemorrhage
and infection, resistance to which is apparently enhanced
in females, including those with ESRD [17, 18].
Treatment time
The effect of treatment time on morbidity and survival
in thrice weekly hemodialyzed patients is controversial.
Previous observational studies showing higher mortal-
ity rates associated with shorter treatment time most
likely were caused by underdialysis [19]. More recent
studies, including a report from the Dialysis Outcome
Practice Pattern Study (DOPPS), showed no significant
effect of treatment time on the risk of mortality when
controlled for dose [20, 21], [abstract; J Am Soc Nephrol
12:343A, 2001]. Uncontrolled observational studies from
Tassin, France, suggest that markedly prolonged treat-
ment times are associated with improved survival [22].
In these studies the beneficial effects of a longer treat-
ment time on control of extracellular fluid volume and/or
blood pressure may play an important role. In the de-
sign of the HEMO Study, treatment time was closely cou-
pled with the patients’ randomized dose target, volume
of urea distribution, and achievable blood flow. As a con-
sequence, the HEMO Study did not provide a favorable
setting for evaluating the effect of treatment time inde-
pendently of these other factors, and cannot provide a
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clear determination of whether the interaction of gen-
der with dose may have resulted from shorter treatment
times for women randomized to the standard dose group.
Other limitations
Because the HEMO Study was designed to test effects
of the interventions in all randomized patients, it has lim-
ited power to address treatment effects in subgroups. In
particular, while the HEMO Study results provide little
or no evidence that the effect of dose depends on body
size independently of gender, we cannot rule out the pos-
sibility of an undetected benefit of the high goal in smaller
patients. The statistical power of the study to detect an
interaction of dose with body size may also have been re-
duced by the exclusion of larger patients who were unable
to achieve a target eKt/V of 1.45 within 4.5 hours.
Owing to an abundance of urban centers, the HEMO
Study included a greater proportion of blacks than in
the general United States ESRD population. As noted
above in this study and by others [2], there was a trend for
the gender-dose interaction to be stronger in non-blacks.
Another similar study with more non-blacks might show
an even greater gender interaction with dose than is
shown here.
Clinical implications
The HEMO Study analysis of dialysis dose interactions
suggests that women, independent of body size, constitute
a subset of patients whose outcome is improved when
treated with higher doses of dialysis. Because the level
of significance must be considered borderline, a product
of multiple comparisons, these results are suggestive, not
proof of a gender effect. This notion is strengthened by
analysis of some, but not all, secondary HEMO outcomes
and by one previous observational report that was gen-
erally consistent with a greater effect of dose in women
[2].
CONCLUSION
After the results of the HEMO Study became known,
further analyses of national data from the USRDS identi-
fied similar interactions between dose and gender consis-
tent with a greater benefit of increased dose in women
within the range of doses investigated by the HEMO
Study [abstract; J Am Soc Nephrol 13:20A, 2002] [8].
Modification of current standards for dialysis adequacy
according to gender should be considered.
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